flibanserin-d4

Flibanserin (T4297), a compound identified as BIMT-17, acts as a complete agonist at the serotonin 5-HT1A receptor, with a binding affinity (Ki) of 1 nM, while functioning as an antagonist at the 5-HT2A receptor with a 49 nM affinity. Flibanserin-D4 represents a deuterium-labeled version of Flibanserin.

Flibanserin-D4-1 is the deuterated form of Flibanserin. Flibanserin (T4297) (BIMT-17) functions as a full agonist at the 5-hydroxytryptamine (5-HT1A) receptor with a Ki of 1 nM, and as an antagonist at the 5-HT2A receptor with a Ki of 49 nM. It binds to dopamine D4 receptors with an affinity ranging from 4 to 24 nM, while showing negligible affinity for various other neurotransmitter receptors and ion channels. Flibanserin (T4297) is being investigated for its potential in treating hypoactive sexual desire disorder (HSDD).

Flibanserin (Girosa) is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury.

Flibanserin (BIMT-17; BIMT-17BS) hydrochloride is an orally active compound that functions as a 5-HT1A receptor agonist (Ki: 1 nM) and a 5-HT2A receptor antagonist (Ki: 49 nM) of 5-hydroxytryptamine. It possesses antidepressant and anxiolytic effects and is used in studies of hypoactive sexual desire (HSDD).